Obesity, High-Molecular-Weight (HMW) Adiponectin, and Metabolic Risk Factors: Prevalence and Gender-Specific Associations in Estonia

Eglit, Triin; Ringmets, Inge; Lember, Margus

doi:10.1371/journal.pone.0073273

Cited by 24 publications

(22 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This suggests that blood adiponectin levels could serve as a potential biomarker for cardiometabolic risk in MUNW, MHO, and MUO individuals that is independent of body weight. This is further supported by another study showing that adiponectin was positively correlated with HDL-c and inversely associated with TG levels, adiposity parameters, insulin resistance, and blood glucose (67).…”

Section: Cytokines and Adipokinessupporting

confidence: 69%

Molecular insights into the role of white adipose tissue in metabolically unhealthy normal weight and metabolically healthy obese individuals

et al. 2014

View full text Add to dashboard Cite

Obesity is a risk factor for the development of type 2 diabetes and cardiovascular disease. However, it is now recognized that a subset of individuals have reduced cardiometabolic risk despite being obese. Paradoxically, a subset of lean individuals is reported to have high risk for cardiometabolic complications. These distinct subgroups of individuals are referred to as metabolically unhealthy normal weight (MUNW) and metabolically healthy obese (MHO). Although the clinical relevance of these subgroups remains debated, evidence shows a critical role for white adipose tissue (WAT) function in the development of these phenotypes. The goal of this review is to provide an overview of our current state of knowledge regarding the molecular and metabolic characteristics of WAT associated with MUNW and MHO. In particular, we discuss the link between different WAT depots, immune cell infiltration, and adipokine production with MUNW and MHO. Furthermore, we also highlight recent molecular insights made with genomic technologies showing that processes such as oxidative phosphorylation, branched-chain amino acid catabolism, and fatty acid β-oxidation differ between these phenotypes. This review provides evidence that WAT function is closely linked with cardiometabolic risk independent of obesity and thus contributes to the development of MUNW and MHO.

show abstract

Section: Cytokines and Adipokinessupporting

confidence: 69%

Molecular insights into the role of white adipose tissue in metabolically unhealthy normal weight and metabolically healthy obese individuals

et al. 2014

View full text Add to dashboard Cite

show abstract

“…From the 27 selected articles, the MHO prevalence was defined as an objective in 14 studies (52%) (11,14,15,17,20,21,23,(25)(26)(27)29,30,34,35).…”

Section: Methodological Quality Of the Studiesmentioning

confidence: 99%

“…The target population was described in four studies (15%) (16,17,24,27). The probability sampling was described in 19 studies (70%) (8,9,(13)(14)(15)(17)(18)(19)(20)(21)(22)(26)(27)(28)(29)31,(33)(34)(35). Nine studies (33%) described the response rate, and of these only four (13,15,16,21) reported rates 786 Prevalence of metabolically healthy obesity J. P. Rey-López et al obesity reviews ≥70%.…”

Section: Methodological Quality Of the Studiesmentioning

confidence: 99%

See 1 more Smart Citation

The prevalence of metabolically healthy obesity: a systematic review and critical evaluation of the definitions used

Rey-López¹,

et al. 2014

View full text Add to dashboard Cite

We performed a systematic review of the prevalence of metabolically healthy obesity (MHO). Medline, Web of Science and EMBASE were searched for original articles from inception to November 2013. Only prospective and cross-sectional studies were included. After screening 478 titles, we selected 55 publications, of which 27 were population-based studies and were used in the narrative synthesis. From the 27 studies, we identified 30 definitions of metabolic health, mainly based on four criteria: blood pressure, high-density lipoprotein cholesterol, triglycerides and plasma glucose. Body mass index ≥30 kg m(-2) was the main indicator used to define obesity (74% of the studies). Overall, MHO prevalence ranged between 6% and 75%. In the studies that stratified the analysis by sex, prevalence was higher in women (seven out of nine studies) and in younger ages (all four studies). One-third of the studies (n = 9) reported the response rate. Of these, four reported a response rate of ≥70% and they showed MHO prevalence estimates between 10% and 51%. The heterogeneity of MHO prevalence estimates described in this paper strengthens calls for the urgent need for a commonly established metabolic health definition.

show abstract

“…In non-obese and obese women, serum RBP-4 was highest among those with visceral adiposity as compared to those without, and levels were not different between the non-obese and obese groups that did not have visceral adiposity (265). MHO individuals also have higher circulating levels of high-molecular weight (HMW) adiponectin (9, 103, 107) and lower FFA (340, 482) as compared to insulin resistant obese individuals. These factors may contribute to the protection from metabolic dysfunction in MHO despite having excess adiposity.…”

Section: Adiposity and Insulin Resistancementioning

confidence: 99%

Contribution of Adipose Tissue Inflammation to the Development of Type 2 Diabetes Mellitus

Burhans

Hagman

Kuzma

et al. 2018

Comprehensive Physiology

275

241

View full text Add to dashboard Cite

The objective of this comprehensive review is to summarize and discuss the available evidence of how adipose tissue inflammation affects insulin sensitivity and glucose tolerance. Low-grade, chronic adipose tissue inflammation is characterized by infiltration of macrophages and other immune cell populations into adipose tissue, and a shift towards more pro-inflammatory subtypes of leukocytes. The infiltration of pro-inflammatory cells in adipose tissue is associated with an increased production of key chemokines such as C-C motif chemokine ligand 2, pro-inflammatory cytokines including tumor necrosis factor α and interleukins 1β and 6, as well as reduced expression of the key insulin sensitizing adipokine, adiponectin. In both rodent models and humans, adipose tissue inflammation is consistently associated with excess fat mass and insulin resistance. In humans, associations with insulin resistance are stronger and more consistent for inflammation in visceral as opposed to subcutaneous fat. Further, genetic alterations in mouse models of obesity that reduce adipose tissue inflammation are – almost without exception - associated with improved insulin sensitivity. However, a dissociation between adipose tissue inflammation and insulin resistance can be observed in very few rodent models of obesity as well as in humans following bariatric surgery- or low-calorie diet-induced weight loss, illustrating that the etiology of insulin resistance is multifactorial. Taken together, adipose tissue inflammation is a key factor in the development of insulin resistance and type 2 diabetes in obesity, along with other factors that likely include inflammation and fat accumulation in other metabolically active tissues.

show abstract

Obesity, High-Molecular-Weight (HMW) Adiponectin, and Metabolic Risk Factors: Prevalence and Gender-Specific Associations in Estonia

Cited by 24 publications

References 37 publications

Molecular insights into the role of white adipose tissue in metabolically unhealthy normal weight and metabolically healthy obese individuals

Molecular insights into the role of white adipose tissue in metabolically unhealthy normal weight and metabolically healthy obese individuals

The prevalence of metabolically healthy obesity: a systematic review and critical evaluation of the definitions used

Contribution of Adipose Tissue Inflammation to the Development of Type 2 Diabetes Mellitus

Contact Info

Product

Resources

About